FAST NEWS: JPMorgan boosts WuXi AppTec stake
The latest: U.S. banking giant JPMorgan purchased 1.57 million Hong Kong-listed shares of WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) for HK$75.33 million ($9.66 million) on Feb. 8, raising its stake in the drug…
Potential U.S. targeting casts shadow over WuXi AppTec family
Proposed U.S. legislation could ban federal agencies and federally funded institutions from buying devices and services from Chinese biotech companies Key Takeaways: WuXi AppTec, which could be banned from doing…
FAST NEWS: WuXi Biologics boosts new projects target
The latest: Contract drug services provider WuXi Biologics (Cayman) Inc. (2269.HK) announced on Wednesday it has raised its guidance for new projects in 2024 from 80 to 110, despite a…
WuXi Bio prescribes share buyback to relieve revenue pain
The pharma services provider has shocked investors with a steep downward revision of its earnings outlook, slashing its full-year revenue growth forecast to just 10% from an initial 30% and…
China’s mRNA pioneer Stemirna faces post-Covid reinvention test
The biopharma company that led the way in Chinese mRNA research is battling a wave of lawsuits and financial woes, including court limits on its founder’s spending Key Takeaways: Flush…
FAST NEWS: JW Therapeutics to expand collaboration with 2Seventy Bio
The latest: Drug maker JW (Cayman) Therapeutics Co. Ltd. (2126.HK) said on Tuesday it is in talks to expand its strategic alliance with 2Seventy Bio (TSVT.US), which began with a partnership established in…
FAST NEWS: JW Therapeutics’ loss narrows on lower selling expenses
The latest: Biotech company JW (Cayman) Therapeutics Co. Ltd. (2126.HK) reported on Tuesday its net loss for the first half of 2023 narrowed 11.4% year-on-year to 380 million yuan ($52.1 million). Looking…